Tyra Biosciences Q2 FY26 net loss widens to $45.56 million; R&D expenses climb to $39.2 million
TYRA•Pipeline timing updates
- Initial Phase 2 results from SURF302 are expected in September, covering safety in more than 40 patients and efficacy in more than 20.
- BEACH301 safety-sentinel readout is now expected at end of Q1 2027, while the achondroplasia study opened a fifth dose level at 0.625 mg/kg.
Q2 loss widens as R&D and G&A rise
- Tyra Biosciences posted a Q2 net loss of $45.6 million, widening from $28.1 million a year earlier; loss per share deepened to $0.69 from $0.47.
- R&D expense climbed 61.27% to $39.2 million, while G&A rose 38.01% to $9.8 million.
- Cash, cash equivalents and marketable securities totaled $353.9 million at June 30, with runway expected into the second half of 2028.
